Fig. 1. Anti-proliferative effect of lenvatinib and vemurafenib in HTh7 and 8505C anaplastic thyroid cancer cells. (A) Single treatment of vemurafenib in BRAFV^600E mutated 8505C cells showed anti-proliferative effect from 0.25 μM concentration. However, HTh7 cells with NRAS mutation represented drug resistance up to 4 μM and abruptly cell viability was decreased from 8 μM. (B) Single treatment of lenvatinib in 8505C and HTh7 cells showed dose dependent anti-proliferative effect. Values presented here are mean value±standard deviation.

Int J Thyroidol 2021;14:127-34 https://doi.org/10.11106/ijt.2021.14.2.127

© 2021 Int J Thyroidol